Skip to content
2000
  1. Home
  2. A-Z Publications
  3. MicroRNA
  4. Volume 13, Issue 3
  5. Article
Volume 13, Issue 3
  • ISSN: 2211-5366
  • E-ISSN: 2211-5374

Abstract

Background

Molecular markers in Colorectal Cancer (CRC) are needed for more accurate classification and personalized treatment. In this way, we investigated the effects of the gene on clinical outcomes of its expression fluctuations and its polymorphism at rs1267623 in CRC.

Methods

In this study, 36.36 percent of patients with CRC were women, and 63.63 percent were men. After the pathology department confirmed the tumor of the samples, the stage and grade of the tumor were determined according to the TNM system. Real-time PCR was used to check the expression of the gene in tumor and non-tumor tissues, and its polymorphism in rs1267623 was also checked using the Tetra-ARMs PCR technique.

Results

The expression of in tumor tissues was significantly higher than in non-tumoral tissues ( = 0.001), indicating an upregulation of gene expression in tumoral tissues. The user's text is empty. Furthermore, there was a significant correlation between expression and tumor stage ( = 0.001), as well as tumor grade ( = 0.003). However, no significant link was found between lymph node metastasis and distant metastasis of gene expression ( = 0.3). Additionally, no mutation was detected in the investigation of rs1267623 polymorphism.

Conclusion

The gene was upregulated in tumoral tissues. Remarkably, no mutation was found in the rs1267623 polymorphism. As a result, this gene can be used as a biomarker in the diagnosis and treatment of CRC.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/mirna/10.2174/0122115366286360240625095932
2024-11-01
2024-11-26

  • From This Site

    /content/journals/mirna/10.2174/0122115366286360240625095932
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ZhangJ. LaiW. LiQ. A novel oncolytic adenovirus targeting Wnt signaling effectively inhibits cancer-stem like cell growth via metastasis, apoptosis and autophagy in HCC models.Biochem. Biophys. Res. Commun.2017491246947710.1016/j.bbrc.2017.07.041 28698142
     [Google Scholar]
  2. RassyE. ParentP. LefortF. BoussiosS. BaciarelloG. PavlidisN. New rising entities in cancer of unknown primary: Is there a real therapeutic benefit?Crit. Rev. Oncol. Hematol.202014710288210.1016/j.critrevonc.2020.102882 32106012
     [Google Scholar]
  3. HuiD. KimS.H. RoquemoreJ. DevR. ChisholmG. BrueraE. Impact of timing and setting of palliative care referral on quality of end‐of‐life care in cancer patients.Cancer2014120111743174910.1002/cncr.28628 24967463
     [Google Scholar]
  4. AtlasS.J. ZaiA.H. AshburnerJ.M. Non-visit-based cancer screening using a novel population management system.J. Am. Board Fam. Med.201427447448510.3122/jabfm.2014.04.130319 25002002
     [Google Scholar]
  5. ChenJ. GuoF. ShiX. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.BMC Cancer201414180210.1186/1471‑2407‑14‑802 25367198
     [Google Scholar]
  6. MarranciA. JiangZ. VitielloM. The landscape of BRAF transcript and protein variants in human cancer.Mol. Cancer20171618510.1186/s12943‑017‑0645‑4 28454577
     [Google Scholar]
  7. GrotheyA. FakihM. TaberneroJ. Management of BRAF-mutant metastatic colorectal cancer: A review of treatment options and evidence-based guidelines.Ann. Oncol.202132895996710.1016/j.annonc.2021.03.206 33836264
     [Google Scholar]
  8. LuuL-J PriceJ BRAF mutation and its importance in colorectal cancer. Advances in the Molecular Understanding of Colorectal Cancer.London: InTechOpen201911810.5772/intechopen.82571
     [Google Scholar]
  9. BarrasD. BRAF mutation in colorectal cancer: An update.Biomark. Cancer20157Suppl. 1912
     [Google Scholar]
  10. AdelekeS. HaslamA. ChoyA. Microsatellite instability testing in colorectal patients with Lynch syndrome: Lessons learned from a case report and how to avoid such pitfalls.Per. Med.202219427728610.2217/pme‑2021‑0128 35708161
     [Google Scholar]
  11. MartinettiD. CostanzoR. KadareS. KRAS and BRAF mutational status in colon cancer from Albanian patients.Diagn. Pathol.20149118710.1186/s13000‑014‑0187‑7 25267307
     [Google Scholar]
  12. ClarkeC.N. KopetzE.S. BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: Clinical characteristics, clinical behavior, and response to targeted therapies.J. Gastrointest. Oncol.201566660667 26697199
     [Google Scholar]
  13. FakihM.G. Metastatic colorectal cancer: Current state and future directions.J. Clin. Oncol.201533161809182410.1200/JCO.2014.59.7633 25918280
     [Google Scholar]
  14. SinicropeF.A. MahoneyM.R. SmyrkT.C. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.J. Clin. Oncol.201331293664367210.1200/JCO.2013.48.9591 24019539
     [Google Scholar]
  15. BarrasD. MissiagliaE. WirapatiP. BRAF V600E mutant colorectal cancer subtypes based on gene expression.Clin. Cancer Res.201723110411510.1158/1078‑0432.CCR‑16‑0140 27354468
     [Google Scholar]
  16. PriceT.J. HardinghamJ.E. LeeC.K. Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer.J. Clin. Oncol.201129192675268210.1200/JCO.2010.34.5520 21646616
     [Google Scholar]
  17. VenderboschS. NagtegaalI.D. MaughanT.S. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: A pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.Clin. Cancer Res.201420205322533010.1158/1078‑0432.CCR‑14‑0332 25139339
     [Google Scholar]
  18. SinicropeF.A. ShiQ. SmyrkT.C. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes.Gastroenterology20151481889910.1053/j.gastro.2014.09.041 25305506
     [Google Scholar]
  19. HirschiB. GallmeierE. ZieschA. MarschallM. KolligsF.T. Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.Mol. Cancer201413112210.1186/1476‑4598‑13‑122 24885690
     [Google Scholar]
  20. HerrR. KöhlerM. AndrlováH. B-Raf inhibitors induce epithelial differentiation in BRAF-mutant colorectal cancer cells.Cancer Res.201575121622910.1158/0008‑5472.CAN‑13‑3686 25381152
     [Google Scholar]
  21. SaridakiZ. SouglakosJ. GeorgouliasV. Prognostic and predictive significance of MSI in stages II/III colon cancer.World J. Gastroenterol.201420226809681410.3748/wjg.v20.i22.6809 24944470
     [Google Scholar]
  22. OsseisM. NehmehW.A. RassyN. Surgery for T4 colorectal cancer in older patients: Determinants of outcomes.J. Pers. Med.2022129153410.3390/jpm12091534 36143319
     [Google Scholar]
  23. FanJ.Z. WangG.F. ChengX.B. Relationship between mismatch repair protein, RAS, BRAF, PIK3CA gene expression and clinicopathological characteristics in elderly colorectal cancer patients.World J. Clin. Cases20219112458246810.12998/wjcc.v9.i11.2458 33889611
     [Google Scholar]
  24. LochheadP. KuchibaA. ImamuraY. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication.J. Natl. Cancer Inst.2013105151151115610.1093/jnci/djt173 23878352
     [Google Scholar]
  25. BoussiosS. OzturkM. MoschettaM. The developing story of predictive biomarkers in colorectal cancer.J. Pers. Med.2019911210.3390/jpm9010012 30736475
     [Google Scholar]
  26. SinicropeF.A. ShiQ. AllegraC.J. Association of DNA mismatch repair and mutations in BRAF and KRAS with survival after recurrence in stage III colon cancers: A secondary analysis of 2 randomized clinical trials.JAMA Oncol.20173447248010.1001/jamaoncol.2016.5469 28006055
     [Google Scholar]
  27. PiccioliP. SerraM. GismondiV. Multiplex tetra-primer amplification refractory mutation system PCR to detect 6 common germline mutations of the MUTYH gene associated with polyposis and colorectal cancer.Clin. Chem.200652473974310.1373/clinchem.2005.060137 16455870
     [Google Scholar]
  28. WonD.D. LeeJ.I. LeeI.K. OhS.T. JungE.S. LeeS.H. The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients.BMC Cancer201717140310.1186/s12885‑017‑3381‑7 28583095
     [Google Scholar]
  29. NakajiY. OkiE. NakanishiR. Prognostic value of BRAF V600E mutation and microsatellite instability in Japanese patients with sporadic colorectal cancer.J. Cancer Res. Clin. Oncol.2017143115116010.1007/s00432‑016‑2275‑4 27672042
     [Google Scholar]
  30. Fariña-SarasquetaA. van LijnschotenG. MoerlandE. The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.Ann. Oncol.201021122396240210.1093/annonc/mdq258 20501503
     [Google Scholar]
  31. LiY. LiW. BRAF mutation is associated with poor clinicopathological outcomes in colorectal cancer: A meta-analysis.Saudi J. Gastroenterol.2017233144
     [Google Scholar]
  32. YangM SchellMJ YeatmanTJ Abstract 3170: BRAF expression is associated with poor survival in colorectal cancers independent of BRAF (V600E) mutation.Cancer Res20197913_Supplement)(Suppl.317010.1158/1538‑7445.AM2019‑3170 31048498
     [Google Scholar]
/content/journals/mirna/10.2174/0122115366286360240625095932
Loading
Evaluation of Fluctuations of BRAF Gene Expression and its Polymorphism at rs1267623 in Colorectal Cancer
MicroRNA 13, 202 (2024); https://doi.org/10.2174/0122115366286360240625095932
/content/journals/mirna/10.2174/0122115366286360240625095932
/content/journals/mirna/10.2174/0122115366286360240625095932
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): biomarker; BRAF gene expression; Colorectal cancer; diagnosis; mutation; polymorphism
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test